Information Provided By:
Fly News Breaks for July 22, 2015
REGN
Jul 22, 2015 | 08:39 EDT
Northland analyst James Kuo started shares of Regeneron Pharmaceuticals with a Market Perform rating and $500 price target. Pointing out that shares are up 34% year-to-date and 80% year-over-year, Kuo prefers to watch the upcoming launch of Praluent from the sidelines.